Highest-materiality recent filing
Zivo Bioscience to voluntarily deregister, cease SEC reporting; CFO and director resign
CFO William Sullivan resigns effective March 30, 2026; board member Alison Cornell resigns immediately as part of cost-cutting measures.
CFO Keith Marchiando resigns; William Sullivan appointed Interim CFO
Keith Marchiando resigns as CFO effective Dec 31, 2025; receives $27,040/mo through Dec 31, 2026.
ZIVO CEO letter highlights algae antioxidant validation and animal health progress
Independent analysis showed ZIVO's algae has nearly double SOD activity vs. a competing algae product.
Director Nola Masterson resigns from Zivo Bioscience board effective August 12, 2025
Ms. Masterson resigned immediately; no disagreement with company operations, policies, or practices.
Zivo Bioscience raises $250k initial tranche in $2M convertible debt offering
Issued $250k bridge promissory note with 10% annual interest, compounded annually; due after 2 years or upon $5M+ equity financing.
Elected John B. Payne and Alison A. Cornell as Class III directors with 1,681,190 and 1,681,001 votes for, respectively; broker non-votes 792,911.
Zivo Bioscience issues 191,698 shares, raises ~$1.5M from accredited investor since Nov 2024
Sold 75,000 shares at $20.19 each to one accredited investor, gross proceeds ~$1.5M.
Zivo Bioscience swaps revenue share obligations for 212,260 shares; director affiliates participate
Company authorized exchange of up to 212,260 shares for cancellation of Participation Agreements with accredited investors.
ZIVO BIOSCIENCE moves principal executive office to Troy, Michigan
Effective January 6, 2025, principal executive office changed to 2125 Butterfield Drive, Suite 100, Troy, MI 48084.
Zivo restructures $277k debt into unsecured notes payable over 24 months at 1%
Debt Settlement Agreements with three creditors executed on Nov 12, 2024.
Zivo Bioscience sells 169,022 unregistered shares at avg $10.44 to accredited investors
Sold 169,022 shares between Aug 22 and Oct 17, 2024, at $8.34 to $16.31 per share (avg $10.44).
ZIVO Bioscience appoints Laith Yaldoo to board, expands to 5 members
Board increased from 4 to 5 members; Laith Yaldoo appointed effective July 11, 2024.
Zivo shareholders elect Masterson as director, ratify BDO, approve say-on-pay
Nola E. Masterson elected Class II director (1,155,796 for, 80,935 withheld; 625,589 broker non-votes).
Zivo Bioscience amends 8-K to correct date typo in director stock award from 2023
Corrects date in Item 1.01 from erroneous date to December 29, 2023.
Adopted 2024 Director Equity Plan (875k shares, auto-increase 5%/yr). Director cash fee raised from $40k to $50k, eligible for restricted stock/RSUs.
On July 11, 2024, the Board of Directors of ZIVO Bioscience Inc., (the “Company”) increased its size from four (4) to five (5) members and appointed Laith Yaldoo to fill the vacancy.
Max materiality 0.80 · Median 0.50 · Most common event other_material